Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.44 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101336 | 0.94 | JAK3 (0.48) | JAK3JAK2JAK1BRAFCYP2D6 | |
| SCHEMBL29540587 | 0.94 | JAK3 (0.48) | JAK3JAK2JAK1BRAFCYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4092161 | 0.86 | JAK3 (0.43) | JAK3JAK2JAK1BRAFCYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4093224 | 0.84 | TEK (0.44) | BRAFTP53ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4082497 | 0.84 | GRM5 (0.48) | — | |
| Trifluoroacetic Acid SCHEMBL4097114 | 0.84 | CTSA (0.36) | BRAFCYP2D6CYP2C9AURKAAURKB | |
| Trifluoroacetic Acid SCHEMBL4088295 | 0.81 | PRKCI (0.41) | JAK3JAK2BRAFCYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4092155 | 0.81 | CAPN1 (0.46) | BRAFCYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL4092018 | 0.81 | BRAF (0.40) | JAK3BRAFCYP2D6CYP2C9AURKA | |
| SCHEMBL29540508 | 0.80 | JAK3 (0.48) | JAK3JAK2JAK1BRAFCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.